Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remzistotug (GSK4381562) Monotherapy and Combination Therapy in Advanced Solid Tumors
NCT05277051Phase 1Active, not recruiting
- Sponsor
- GSK
- Start
- Mar 2022
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 1, open-label trial of remzistotug in solid tumor (8 arms), sponsored by GSK. Primary endpoints: Dose-Limiting Toxicities at 21 days and Adverse Events and Serious Adverse Events at 27 months. Started Mar 2022; status: active, not recruiting.
02
Drugs
remzistotug
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05277051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05277051.